Shares of biotech company 10x Genomics (NASDAQ:TXG ... Revenue declined by 10% year on year, reflecting ongoing weakness in demand, particularly in instrument sales, though consumables performed ...

Get access to 10+ additional ProTips and comprehensive valuation metrics with InvestingPro's detailed research report. In other recent news, 10X Genomics announced preliminary fourth-quarter sales ...

Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the life science tools and diagnostics group to be down ...

10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million from Chromium instruments and $13.43 million from Spatial instruments.

Potential delays in adoption for new products like Visium HD and GEM-X. Macroeconomic uncertainties could impact spending in academia and biopharma. 10x Genomics delivered strong Q4 2023 results ...

20:11 EST Cathie Wood’s ARK Investment buys 120K shares of 10x Genomics (TXG) today Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (LSE ... of all funds dedicated to 0A88 is 0.10%, an increase of 21.48%. Total shares owned ...